Harvard Apparatus Regenerative Technology (HRGN) is a clinical-stage biotech developing regenerative medicine treatments for damaged organs, with a primary focus on the esophagus. HRGN's lead product is the Cellspan Esophageal Implant (CEI), a temporary polyurethane scaffold seeded with the patient's own stem cells that bridges the gap left after diseased esophagus is removed. Once implanted, the patient's body regenerates esophageal tissue around the scaffold over several weeks, at which point the scaffold is removed — leaving no permanent implant. The CEI is intended as an alternative to current surgical options like gastric pull-up and colonic interposition, both of which sacrifice other organs and carry high complication rates. HRGN has FDA approval for a 10-patient Phase 1 trial, with sites activated at Mayo Clinic, University of Michigan, and USC, though no patients have been enrolled yet. HRGN also has an earlier-stage program targeting pediatric esophageal atresia, in collaboration with researchers in Beijing, and preclinical work on colon regeneration and uterine repair. If approved, HRGN plans to sell the CEI directly to hospitals at roughly $250,000 per unit in the U.S., a low-volume, high-price model given the roughly 5,000 annual esophagectomies in the U.S. HRGN holds FDA and EMA Orphan Drug Designations, providing market exclusivity upon approval. HRGN also operates a small dietary supplements subsidiary in Hong Kong, which is not a meaningful part of the business.